Thalidomide.
| Publicado en: | Lancet Vol. 363; no. 9423; pp. 1802 - 1812 |
|---|---|
| Autores principales: | , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Lancet
5/29/2004
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106566793&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106566793 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01406736 LAN jtl: Lancet issn: 01406736 maglogo: N pubinfo: dt: 5/29/2004 vid: 363 iid: 9423 pid: 1297 pub: Lancet place: Philadelphia, Pennsylvania artinfo: ui: 106566793 106566793 2005022222 10.1016/s0140-6736(04)16308-3 NLM15172781 106566793 ppf: 1802 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Thalidomide. aug: au: Franks ME Macpherson GR Figg WD affil: Urologic Oncology Branch and Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD sug: subj: Thalidomide Therapeutic Use Neoplasms Drug Therapy Skin Diseases Drug Therapy Thalidomide Administration and Dosage Thalidomide Adverse Effects Thalidomide Analogs and Derivatives Thalidomide Pharmacodynamics pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|